
Larimar Therapeutics, Inc. — Investor Relations & Filings
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-19 | English | |
| 10-Q | 2026-05-14 | English | |
| 8-K | 2026-05-14 | English | |
| S-8 - Larimar Therapeutics, Inc. (0001374690) (Filer) | 2026-03-19 | English | |
| 10-K - Larimar Therapeutics, Inc. (0001374690) (Filer) | 2026-03-19 | English | |
| 8-K - Larimar Therapeutics, Inc. (0001374690) (Filer) | 2026-03-19 | English |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46557399 | 8-K | 2026-05-19 | English | ||
| 46282456 | 10-Q | 2026-05-14 | English | ||
| 45966119 | 8-K | 2026-05-14 | English | ||
| 32989784 | S-8 - Larimar Therapeutics, Inc. (0001374690) (Filer) | 2026-03-19 | English | ||
| 32989111 | 10-K - Larimar Therapeutics, Inc. (0001374690) (Filer) | 2026-03-19 | English | ||
| 32985493 | 8-K - Larimar Therapeutics, Inc. (0001374690) (Filer) | 2026-03-19 | English | ||
| 32890859 | 4 - LARIMAR THERAPEUTICS, INC. (0001374690) (Filer) | 2026-03-03 | English | ||
| 32890855 | 4 - LARIMAR THERAPEUTICS, INC. (0001374690) (Filer) | 2026-03-02 | English | ||
| 32890857 | 4 - LARIMAR THERAPEUTICS, INC. (0001374690) (Filer) | 2026-03-02 | English | ||
| 32890858 | 4 - LARIMAR THERAPEUTICS, INC. (0001374690) (Filer) | 2026-03-02 | English | ||
| 32890863 | 8-K - LARIMAR THERAPEUTICS, INC. (0001374690) (Filer) | 2026-02-26 | English | ||
| 32890866 | 8-K - LARIMAR THERAPEUTICS, INC. (0001374690) (Filer) | 2026-02-24 | English | ||
| 29193640 | SCHEDULE 13G/A Filing | 2026-02-12 | English | ||
| 29193648 | 4 Filing | 2026-01-27 | English | ||
| 29193643 | 4 Filing | 2026-01-27 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Asarina Pharma AB
A biotechnology company in liquidation, formerly focused on…
|
ASAP | SE | Professional, scientific and te… |
|
Atara Biotherapeutics, Inc.
Develops off-the-shelf allogeneic T-cell immunotherapies fo…
|
ATRA | US | Professional, scientific and te… |
|
ATUM CO., LTD.
An integrated biologics development partner offering servic…
|
355690 | KR | Professional, scientific and te… |
|
AUREKA LIMITED
Accelerates drug discovery and development using AI and com…
|
AKA | AU | Professional, scientific and te… |
|
Avalo Therapeutics, Inc.
Clinical-stage biotech developing treatments for immune-med…
|
AVTX | US | Professional, scientific and te… |
|
Avalyn Pharma Inc.
Developing innovative inhaled therapies for rare respirator…
|
AVLN | US | Professional, scientific and te… |
|
Azenta, Inc.
Offers sample management, storage, and multiomics solutions…
|
AZTA | US | Professional, scientific and te… |
|
Baijin Life Science Holdings Limited
An investment holding company operating in biopharmaceutica…
|
1466 | HK | Professional, scientific and te… |
|
BCAL DIAGNOSTICS LIMITED
Developing a non-invasive blood test for early breast cance…
|
BDX | AU | Professional, scientific and te… |
|
BEBETTER MED INC.
Develops small molecule therapeutics for oncology, metaboli…
|
688759 | CN | Professional, scientific and te… |
Larimar Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33359/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33359 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33359 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33359 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33359}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Larimar Therapeutics, Inc. (id: 33359)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.